ARIADNA CUEVAS FIALLO,Agustín Bienvenido Lage Dávila,Airama Albisa Novo,Ernesto Chico Véliz,GISELA MARÍA GONZÁLES MARINELLO,GRYSSELL MARÍA RODRÍGUEZ MARTÍNEZ,Lisel Viña Rodríguez,Loany Calvo González
申请号：
BRPI0813662
公开号：
BRPI0813662B1
申请日:
2008.06.26
申请国别(地区):
BR
年份:
2019
代理人:
摘要：
Vaccine composition, process for obtaining a vaccine composition, and use of a vaccine composition The present invention relates to the field of biotechnology and more specifically to human health. In particular, the present invention describes a vaccine composition for its therapeutic use in cancer patients. The vaccine composition described in the present invention is active in a chemical conjugate between recombinant human epidermal growth factor (hregf) and recombinant protein p64k. Further, specific conditions for carrying out a conjugation reaction are described which enable said controlled conjugate to be obtained in a controlled and reproducible manner. In another aspect, the present invention relates to a process for the purification of the chemical conjugate which not only brings greater purity to the therapeutic vaccine composition, but surprisingly increases immunological activity, causing significant increases in anti-egf antibody titers in humans. Additionally the present invention provides the methodology for achieving a vaccine preparation with more than one dose presentation type (total milligrams of egf-p64k / vial conjugates). This versatility in the presentation of the vaccine preparation allows to increase the immunization dose per patient, but this should increase the frequency of immunization and / or the number of immunization sites. Finally, the present invention embodies a sanitary process for obtaining the parenterally administered cancer therapy vaccine preparation.composição vacinal, processo para a obtenção de uma composição vacinal, e, uso de uma composição vacinal a presente invenção se refere ao ramo da biotecnologia e mais especificamente à saúde humana. particularmente, a presente invenção descreve uma composição vacinal para seu uso terapêutico em pacientes de câncer. a composição vacinal descrita na presente invenção tem como principio ativo um conjugado químico entre o fator de crescimento epidérmico humano recombinante (hregf)
